FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1425-1436 September 30, 2004 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Pulmonary arterial hypertension is a disease of the small pulmonary arteries that is characterized by vascular proliferation and remodeling.^1,2 It results in a progressive increase in pulmonary vascular resistance and, ultimately, right ventricular failure and death. A diagnosis of primary (or idiopathic) pulmonary hypertension is made when no known risk factor is identified.^3,4 The diagnostic classification of pulmonary arterial hypertension is described in Table 1.³ Despite recent major improvements in symptomatic treatments, no current treatment cures this devastating condition.^{1,2,5,6,7,8,9} However, during the past 20 years, treatment options for patients with the disease have evolved to help prolong their survival . . . [Full Text of this Article]

Pathophysiological Features

Natural History and Survival

Therapeutic Strategies

Basic Therapy

Calcium-Channel Blockers

Prostacyclin Therapy

Intravenous Prostacyclin

Subcutaneous Treprostinil

Oral Beraprost

Inhaled Iloprost

Endothelin-Receptor Antagonists

Bosentan

Sitaxsentan and Ambrisentan

Potential Future Therapies

Nitric Oxide

Sildenafil

Vasoactive Intestinal Peptide

Selective Serotonin-Reuptake Inhibitors

Combination Therapy

Treatment Algorithms

Source Information

From Centre des Maladies Vasculaires Pulmonaires, Unité Propre de Recherche de l'Enseignement Superieur EA2705, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine-Béclère, Université Paris-Sud, Assistance Publique–Hôpitaux de Paris, Clamart, France.

Address reprint requests to Dr. Humbert at the Service de Pneumologie, Hôpital Antoine-Béclère, 157 Rue de la Porte de Trivaux, 92140 Clamart, France, or at marc.humbert@abc.aphp.fr.

Related Letters:

Treatment of Pulmonary Arterial Hypertension
Huisman A.-M., Vreugdenhil S. A., van Paassen H. C., Humbert M., Sitbon O., Simonneau G.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:308-309, Jan 20, 2005. Correspondence

This article has been cited by other articles:

• Montani, D., Jais, X., Price, L. C., Achouh, L., Degano, B., Mercier, O., Mussot, S., Fadel, E., Dartevelle, P., Sitbon, O., Simonneau, G., Humbert, M. (2009). Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 34: 1348-1356 [Abstract] [Full Text]  
• Oudiz, R. J., Galie, N., Olschewski, H., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Harrison, B. C., Despain, D., Dufton, C., Rubin, L. J., for the ARIES Study Group, (2009). Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.. J Am Coll Cardiol 54: 1971-1981 [Abstract] [Full Text]  
• Gruenig, E., Michelakis, E., Vachiery, J.-L., Vizza, C. D., Meyer, F. J., Doelberg, M., Bach, D., Dingemanse, J., Galie, N. (2009). Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS-1 Study. J Clin Pharmacol 49: 1343-1352 [Abstract] [Full Text]  
• Humbert, M., Rubin, L. J. (2009). Combining evidence and experience in pulmonary hypertension. ERR 18: 135-136 [Full Text]  
• Handoko, M.L., de Man, F.S., Happe, C.M., Schalij, I., Musters, R.J.P., Westerhof, N., Postmus, P.E., Paulus, W.J., van der Laarse, W.J., Vonk-Noordegraaf, A. (2009). Opposite Effects of Training in Rats With Stable and Progressive Pulmonary Hypertension. Circulation 120: 42-49 [Abstract] [Full Text]  
• Robbins, I. M., Newman, J. H., Johnson, R. F., Hemnes, A. R., Fremont, R. D., Piana, R. N., Zhao, D. X., Byrne, D. W. (2009). Association of the Metabolic Syndrome With Pulmonary Venous Hypertension. Chest 136: 31-36 [Abstract] [Full Text]  
• Mouchaers, K. T. B., Schalij, I., Versteilen, A. M. G., Hadi, A. M., van Nieuw Amerongen, G. P., van Hinsbergh, V. W. M., Postmus, P. E., van der Laarse, W. J., Vonk-Noordegraaf, A. (2009). Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 297: H200-H207 [Abstract] [Full Text]  
• Galie, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., Frumkin, L., Barst, R. J., on behalf of the Pulmonary Arterial Hypertension a, (2009). Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation 119: 2894-2903 [Abstract] [Full Text]  
• Khaldi, H., Marchand-Adam, S., Kannengiesser, C., Fabre, A., Debray, M. P., Danel, C., Gougerot-Pocidalo, M-A., El Benna, J., Humbert, M., Aubier, M., Crestani, B. (2009). Diffuse interstitial pneumonia and pulmonary hypertension: a novel manifestation of chronic granulomatous disease. Eur Respir J 33: 1498-1502 [Abstract] [Full Text]  
• McLaughlin, V., Humbert, M., Coghlan, G., Nash, P., Steen, V. (2009). Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 48: iii25-iii31 [Abstract] [Full Text]  
• Brock, M., Trenkmann, M., Gay, R. E., Michel, B. A., Gay, S., Fischler, M., Ulrich, S., Speich, R., Huber, L. C. (2009). Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway. Circ. Res. 104: 1184-1191 [Abstract] [Full Text]  
• PELED, N., SHITRIT, D., FOX, B. D., SHLOMI, D., AMITAL, A., BENDAYAN, D., KRAMER, M. R. (2009). Peripheral Arterial Stiffness and Endothelial Dysfunction in Idiopathic and Scleroderma Associated Pulmonary Arterial Hypertension. The Journal of Rheumatology 36: 970-975 [Abstract] [Full Text]  
• Faoro, V., Boldingh, S., Moreels, M., Martinez, S., Lamotte, M., Unger, P., Brimioulle, S., Huez, S., Naeije, R. (2009). Bosentan Decreases Pulmonary Vascular Resistance and Improves Exercise Capacity in Acute Hypoxia. Chest 135: 1215-1222 [Abstract] [Full Text]  
• Kimura, S., Egashira, K., Chen, L., Nakano, K., Iwata, E., Miyagawa, M., Tsujimoto, H., Hara, K., Morishita, R., Sueishi, K., Tominaga, R., Sunagawa, K. (2009). Nanoparticle-Mediated Delivery of Nuclear Factor {kappa}B Decoy Into Lungs Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension. Hypertension 53: 877-883 [Abstract] [Full Text]  
• Humbert, M. (2009). Update in Pulmonary Hypertension 2008. Am. J. Respir. Crit. Care Med. 179: 650-656 [Full Text]  
• CELLA, G., VIANELLO, F., COZZI, F., MAROTTA, H., TONA, F., SAGGIORATO, G., IQBAL, O., FAREED, J. (2009). Effect of Bosentan on Plasma Markers of Endothelial Cell Activity in Patients with Secondary Pulmonary Hypertension Related to Connective Tissue Diseases. The Journal of Rheumatology 36: 760-767 [Abstract] [Full Text]  
• Angelini, D. J., Su, Q., Yamaji-Kegan, K., Fan, C., Skinner, J. T., Champion, H. C., Crow, M. T., Johns, R. A. (2009). Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELM{alpha}) induces the vascular and hemodynamic changes of pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 296: L582-L593 [Abstract] [Full Text]  
• Beghetti, M., Galie, N. (2009). Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.. J Am Coll Cardiol 53: 733-740 [Abstract] [Full Text]  
• Rich, S. (2009). The Effects of Vasodilators in Pulmonary Hypertension: Pulmonary Vascular or Peripheral Vascular?. Circ Heart Fail 2: 145-150 [Full Text]  
• Humbert, M. (2009). More pressure on pulmonary hypertension. ERR 18: 1-3 [Full Text]  
• Souza, R., Jardim, C. (2009). Trends in pulmonary arterial hypertension. ERR 18: 7-12 [Full Text]  
• Bogaard, H. J., Abe, K., Vonk Noordegraaf, A., Voelkel, N. F. (2009). The Right Ventricle Under Pressure: Cellular and Molecular Mechanisms of Right-Heart Failure in Pulmonary Hypertension. Chest 135: 794-804 [Abstract] [Full Text]  
• Beghetti, M. (2009). Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs. ERR 18: 18-23 [Abstract] [Full Text]  
• Lang, I. M. (2009). Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. ERR 18: 24-28 [Abstract] [Full Text]  
• Olschewski, H. (2009). Inhaled iloprost for the treatment of pulmonary hypertension. ERR 18: 29-34 [Abstract] [Full Text]  
• Ghofrani, H. A., Grimminger, F. (2009). Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. ERR 18: 35-41 [Abstract] [Full Text]  
• Montani, D., Price, L. C., Girerd, B., Chinet, T., Lacombe, P., Simonneau, G., Humbert, M. (2009). Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. ERR 18: 42-46 [Abstract] [Full Text]  
• Galie, N., Manes, A., Negro, L., Palazzini, M., Bacchi-Reggiani, M. L., Branzi, A. (2009). A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30: 394-403 [Abstract] [Full Text]  
• Stolz, D., Tamm, M. (2009). From the authors. Eur Respir J 33: 452-453 [Full Text]  
• Zhu, B., Zhang, L., Alexeyev, M., Alvarez, D. F., Strada, S. J., Stevens, T. (2009). Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. Am. J. Physiol. Lung Cell. Mol. Physiol. 296: L220-L228 [Abstract] [Full Text]  
• de Jesus Perez, V. A., Alastalo, T.-P., Wu, J. C., Axelrod, J. D., Cooke, J. P., Amieva, M., Rabinovitch, M. (2009). Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-{beta}-catenin and Wnt-RhoA-Rac1 pathways. JCB 184: 83-99 [Abstract] [Full Text]  
• Montani, D., Price, L. C., Dorfmuller, P., Achouh, L., Jais, X., Yaici, A., Sitbon, O., Musset, D., Simonneau, G., Humbert, M. (2009). Pulmonary veno-occlusive disease. Eur Respir J 33: 189-200 [Abstract] [Full Text]  
• Degano, B., Yaici, A., Le Pavec, J., Savale, L., Jais, X., Camara, B., Humbert, M., Simonneau, G., Sitbon, O. (2009). Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 33: 92-98 [Abstract] [Full Text]  
• Gilbert, C., Brown, M. C. J., Cappelleri, J. C., Carlsson, M., McKenna, S. P. (2009). Estimating a Minimally Important Difference in Pulmonary Arterial Hypertension Following Treatment With Sildenafil. Chest 135: 137-142 [Abstract] [Full Text]  
• Meads, D. M., McKenna, S. P., Doughty, N., Das, C., Gin-Sing, W., Langley, J., Pepke-Zaba, J. (2008). The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 32: 1513-1519 [Abstract] [Full Text]  
• Papakonstantinou, E., Kouri, F. M., Karakiulakis, G., Klagas, I., Eickelberg, O. (2008). Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur Respir J 32: 1504-1512 [Abstract] [Full Text]  
• Spence, R., Mandagere, A., Dufton, C., Venitz, J. (2008). Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers. J Clin Pharmacol 48: 1451-1459 [Abstract] [Full Text]  
• Benza, R., Biederman, R., Murali, S., Gupta, H. (2008). Role of Cardiac Magnetic Resonance Imaging in the Management of Patients With Pulmonary Arterial Hypertension. J Am Coll Cardiol 52: 1683-1692 [Abstract] [Full Text]  
• Rich, S., Rabinovitch, M. (2008). Diagnosis and Treatment of Secondary (Non-Category 1) Pulmonary Hypertension. Circulation 118: 2190-2199 [Full Text]  
• Leuchte, H. H., Baezner, C., Baumgartner, R. A., Bevec, D., Bacher, G., Neurohr, C., Behr, J. (2008). Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32: 1289-1294 [Abstract] [Full Text]  
• Hrometz, S. L, Shields, K. M (2008). Role of Ambrisentan in the Management of Pulmonary Hypertension. The Annals of Pharmacotherapy 42: 1653-1659 [Abstract] [Full Text]  
• Simonneau, G., Rubin, L. J., Galie, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., Cossons, N., Sitbon, O., Badesch, D. B., for the PACES Study Group, (2008). Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial. ANN INTERN MED 149: 521-530 [Abstract] [Full Text]  
• Peinado, V. I., Pizarro, S., Barbera, J. A. (2008). Pulmonary Vascular Involvement in COPD. Chest 134: 808-814 [Abstract] [Full Text]  
• Sevilla-Perez, J., Konigshoff, M., Kwapiszewska, G., Amarie, O. V., Seeger, W., Weissmann, N., Schermuly, R. T., Morty, R. E., Eickelberg, O. (2008). Shroom expression is attenuated in pulmonary arterial hypertension. Eur Respir J 32: 871-880 [Abstract] [Full Text]  
• Benza, R. L., Barst, R. J., Galie, N., Frost, A., Girgis, R. E., Highland, K. B., Strange, C., Black, C. M., Badesch, D. B., Rubin, L., Fleming, T. R., Naeije, R. (2008). Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension: A 1-Year, Prospective, Open-Label Observation of Outcome and Survival. Chest 134: 775-782 [Abstract] [Full Text]  
• Humbert, M., Hoeper, M. M. (2008). Severe Pulmonary Arterial Hypertension: A Forme Fruste of Cancer?. Am. J. Respir. Crit. Care Med. 178: 551-552 [Full Text]  
• Ghofrani, H. A., Wilkins, M. W., Rich, S. (2008). Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension. Circulation 118: 1195-1201 [Abstract] [Full Text]  
• Stolz, D., Rasch, H., Linka, A., Di Valentino, M., Meyer, A., Brutsche, M., Tamm, M. (2008). A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32: 619-628 [Abstract] [Full Text]  
• Nickel, N., Kempf, T., Tapken, H., Tongers, J., Laenger, F., Lehmann, U., Golpon, H., Olsson, K., Wilkins, M. R., Gibbs, J. S. R., Hoeper, M. M., Wollert, K. C. (2008). Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 178: 534-541 [Abstract] [Full Text]  
• Opitz, C. F., Ewert, R., Kirch, W., Pittrow, D. (2008). Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?. Eur Heart J 29: 1936-1948 [Abstract] [Full Text]  
• Boutet, K., Montani, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M. (2008). Review: Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2: 249-265 [Abstract]  
• Provencher, S., Herve, P., Sitbon, O., Humbert, M., Simonneau, G., Chemla, D. (2008). Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J 32: 393-398 [Abstract] [Full Text]  
• Suntharalingam, J., Treacy, C. M., Doughty, N. J., Goldsmith, K., Soon, E., Toshner, M. R., Sheares, K. K., Hughes, R., Morrell, N. W., Pepke-Zaba, J. (2008). Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest 134: 229-236 [Abstract] [Full Text]  
• Benza, R. L., Rayburn, B. K., Tallaj, J. A., Pamboukian, S. V., Bourge, R. C. (2008). Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension: Long-term Efficacy and Combination With Bosentan. Chest 134: 139-145 [Abstract] [Full Text]  
• Perros, F., Montani, D., Dorfmuller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J., Mazmanian, M., Fadel, E., Mussot, S., Mercier, O., Herve, P., Emilie, D., Eddahibi, S., Simonneau, G., Souza, R., Humbert, M. (2008). Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 178: 81-88 [Abstract] [Full Text]  
• Sztrymf, B., Coulet, F., Girerd, B., Yaici, A., Jais, X., Sitbon, O., Montani, D., Souza, R., Simonneau, G., Soubrier, F., Humbert, M. (2008). Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. Am. J. Respir. Crit. Care Med. 177: 1377-1383 [Abstract] [Full Text]  
• Galie, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Gerber, M. J., Dufton, C., Wiens, B. L., Rubin, L. J., for the Ambrisentan in Pulmonary Arterial Hyperten, (2008). Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 117: 3010-3019 [Abstract] [Full Text]  
• MacKnight, B., Martinez, E. A., Simon, B. A. (2008). Anesthetic Management of Patients With Pulmonary Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 12: 91-96 [Abstract]  
• Syeda, F., Tullis, E., Slutsky, A. S., Zhang, H. (2008). Human neutrophil peptides upregulate expression of COX-2 and endothelin-1 by inducing oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 294: H2769-H2774 [Abstract] [Full Text]  
• Shah, S. J., Thenappan, T., Rich, S., Tian, L., Archer, S. L., Gomberg-Maitland, M. (2008). Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. Circulation 117: 2475-2483 [Abstract] [Full Text]  
• Humbert, M. (2008). Update in Pulmonary Arterial Hypertension 2007. Am. J. Respir. Crit. Care Med. 177: 574-579 [Full Text]  
• Souza, R., Humbert, M., Sztrymf, B., Jais, X., Yaici, A., Le Pavec, J., Parent, F., Herve, P., Soubrier, F., Sitbon, O., Simonneau, G. (2008). Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 31: 343-348 [Abstract] [Full Text]  
• Petersen, B., Deja, M., Bartholdy, R., Donaubauer, B., Laudi, S., Francis, R. C. E., Boemke, W., Kaisers, U., Busch, T. (2008). Inhalation of the ETA receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R601-R605 [Abstract] [Full Text]  
• Ivy, D. D., Doran, A. K., Smith, K. J., Mallory, G. B. Jr, Beghetti, M., Barst, R. J., Brady, D., Law, Y., Parker, D., Claussen, L., Abman, S. H. (2008). Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. J Am Coll Cardiol 51: 161-169 [Abstract] [Full Text]  
• Otterdal, K., Andreassen, A. K., Yndestad, A., Oie, E., Sandberg, W. J., Dahl, C. P., Pedersen, T. M., Ueland, T., Gullestad, L., Brosstad, F. R., Aukrust, P., Damas, J. K. (2008). Raised LIGHT Levels in Pulmonary Arterial Hypertension: Potential Role in Thrombus Formation. Am. J. Respir. Crit. Care Med. 177: 202-207 [Abstract] [Full Text]  
• Obata, H., Sakai, Y., Ohnishi, S., Takeshita, S., Mori, H., Kodama, M., Kangawa, K., Aizawa, Y., Nagaya, N. (2008). Single Injection of a Sustained-release Prostacyclin Analog Improves Pulmonary Hypertension in Rats. Am. J. Respir. Crit. Care Med. 177: 195-201 [Abstract] [Full Text]  
• Pepke-Zaba, J., Gilbert, C., Collings, L., Brown, M. C. J. (2008). Sildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension. Chest 133: 183-189 [Abstract] [Full Text]  
• Sitbon, O., Lascoux-Combe, C., Delfraissy, J.-F., Yeni, P. G., Raffi, F., De Zuttere, D., Gressin, V., Clerson, P., Sereni, D., Simonneau, G. (2008). Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era. Am. J. Respir. Crit. Care Med. 177: 108-113 [Abstract] [Full Text]  
• Thenappan, T., Shah, S. J., Rich, S., Gomberg-Maitland, M. (2007). A USA-based registry for pulmonary arterial hypertension: 1982 2006. Eur Respir J 30: 1103-1110 [Abstract] [Full Text]  
• Ostergaard, L., Stankevicius, E., Andersen, M. R., Eskildsen-Helmond, Y., Ledet, T., Mulvany, M. J., Simonsen, U. (2007). Diminished NO release in chronic hypoxic human endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 293: H2894-H2903 [Abstract] [Full Text]  
• Price, L. C., Forrest, P., Sodhi, V., Adamson, D. L., Nelson-Piercy, C., Lucey, M., Howard, L. S. (2007). Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth 99: 552-555 [Abstract] [Full Text]  
• McMurtry, M. S., Bonnet, S., Michelakis, E. D., Bonnet, S., Haromy, A., Archer, S. L. (2007). Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L933-L940 [Abstract] [Full Text]  
• Ito, T., Okada, T., Miyashita, H., Nomoto, T., Nonaka-Sarukawa, M., Uchibori, R., Maeda, Y., Urabe, M., Mizukami, H., Kume, A., Takahashi, M., Ikeda, U., Shimada, K., Ozawa, K. (2007). Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. Circ. Res. 101: 734-741 [Abstract] [Full Text]  
• Huang, S., DeSantis, E. R. H. (2007). Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm 64: 1922-1926 [Abstract] [Full Text]  
• Oudiz, R. J., Roveran, G., Hansen, J. E., Sun, X.-G., Wasserman, K. (2007). Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Eur J Heart Fail 9: 917-921 [Abstract] [Full Text]  
• Kuwano, K., Hashino, A., Asaki, T., Hamamoto, T., Yamada, T., Okubo, K., Kuwabara, K. (2007). 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug. J. Pharmacol. Exp. Ther. 322: 1181-1188 [Abstract] [Full Text]  
• Patel, H. H., Zhang, S., Murray, F., Suda, R. Y. S., Head, B. P., Yokoyama, U., Swaney, J. S., Niesman, I. R., Schermuly, R. T., Pullamsetti, S. S., Thistlethwaite, P. A., Miyanohara, A., Farquhar, M. G., Yuan, J. X.-J., Insel, P. A. (2007). Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J. 21: 2970-2979 [Abstract] [Full Text]  
• White, R. J., Meoli, D. F., Swarthout, R. F., Kallop, D. Y., Galaria, I. I., Harvey, J. L., Miller, C. M., Blaxall, B. C., Hall, C. M., Pierce, R. A., Cool, C. D., Taubman, M. B. (2007). Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L583-L590 [Abstract] [Full Text]  
• Smith, V., De Pauw, M., Brusselle, G., Van Praet, J., De Keyser, F. (2007). Re: Pulmonary arterial hypertension in connective tissue diseases. Rheumatology (Oxford) 46: 1510-1510 [Full Text]  
• Ito, T., Okada, T., Mimuro, J., Miyashita, H., Uchibori, R., Urabe, M., Mizukami, H., Kume, A., Takahashi, M., Ikeda, U., Sakata, Y., Shimada, K., Ozawa, K. (2007). Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats. Hypertension 50: 531-536 [Abstract] [Full Text]  
• Vermeersch, P., Buys, E., Pokreisz, P., Marsboom, G., Ichinose, F., Sips, P., Pellens, M., Gillijns, H., Swinnen, M., Graveline, A., Collen, D., Dewerchin, M., Brouckaert, P., Bloch, K. D., Janssens, S. (2007). Soluble Guanylate Cyclase-{alpha}1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia. Circulation 116: 936-943 [Abstract] [Full Text]  
• Humbert, M., Khaltaev, N., Bousquet, J., Souza, R. (2007). Pulmonary Hypertension: From an Orphan Disease to a Public Health Problem. Chest 132: 365-367 [Full Text]  
• Humbert, M. (2007). Dual endothelin receptor antagonism: setting standards in PAH. ERR 16: 13-18 [Abstract] [Full Text]  
• Humbert, M., Segal, E. S., Kiely, D. G., Carlsen, J., Schwierin, B., Hoeper, M. M. (2007). Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30: 338-344 [Abstract] [Full Text]  
• Yu, E. P K, Ostor, A. J K, Hall, F. C (2007). Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis. Ann Rheum Dis 66: 1122-1123 [Full Text]  
• Humbert, M. (2007). The burden of pulmonary hypertension. Eur Respir J 30: 1-2 [Full Text]  
• Zakrzewicz, A., Hecker, M., Marsh, L. M., Kwapiszewska, G., Nejman, B., Long, L., Seeger, W., Schermuly, R. T., Morrell, N. W., Morty, R. E., Eickelberg, O. (2007). Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension. Circulation 115: 2957-2968 [Abstract] [Full Text]  
• Etz, C. D., Welp, H. A., Tjan, T. D.T., Hoffmeier, A., Weigang, E., Scheld, H. H., Schmid, C. (2007). Medically Refractory Pulmonary Hypertension: Treatment With Nonpulsatile Left Ventricular Assist Devices. Ann. Thorac. Surg. 83: 1697-1705 [Abstract] [Full Text]  
• Perros, F., Dorfmuller, P., Souza, R., Durand-Gasselin, I., Godot, V., Capel, F., Adnot, S., Eddahibi, S., Mazmanian, M., Fadel, E., Herve, P., Simonneau, G., Emilie, D., Humbert, M. (2007). Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 29: 937-943 [Abstract] [Full Text]  
• Remillard, C. V., Tigno, D. D., Platoshyn, O., Burg, E. D., Brevnova, E. E., Conger, D., Nicholson, A., Rana, B. K., Channick, R. N., Rubin, L. J., O'Connor, D. T., Yuan, J. X.-J. (2007). Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am. J. Physiol. Cell Physiol. 292: C1837-C1853 [Abstract] [Full Text]  
• Kerbaul, F., Brimioulle, S., Rondelet, B., Dewachter, C., Hubloue, I., Naeije, R. (2007). How Prostacyclin Improves Cardiac Output in Right Heart Failure in Conjunction with Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. 175: 846-850 [Abstract] [Full Text]  
• Wipff, J., Kahan, A., Hachulla, E., Sibilia, J., Cabane, J., Meyer, O., Mouthon, L., Guillevin, L., Junien, C., Boileau, C., Allanore, Y. (2007). Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 46: 622-625 [Abstract] [Full Text]  
• Oka, M., Homma, N., Taraseviciene-Stewart, L., Morris, K. G., Kraskauskas, D., Burns, N., Voelkel, N. F., McMurtry, I. F. (2007). Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats. Circ. Res. 100: 923-929 [Abstract] [Full Text]  
• Jardim, C., Rochitte, C. E., Humbert, M., Rubenfeld, G., Jasinowodolinski, D., Carvalho, C. R. R., Souza, R. (2007). Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study. Eur Respir J 29: 476-481 [Abstract] [Full Text]